Blockchain could galvanize COVID-19 impacted healthcare supply chains: GlobalData
Blockchain technology could prove to be the missing link for global healthcare supply chains exposed by the COVID-19 pandemic in building resilience and galvanizing efficiency, transparency and authenticity, according to market research firm, GlobalData.
The COVID-19 pandemic has wreaked havoc on almost every part of the healthcare industry's supply chains and has rendered many organizations -- especially those who rely heavily on markets such as India and China for raw materials or finished products -- vulnerable, the firm said.
The current outbreak has, therefore, created a "huge stress test" for the healthcare industry and the desperate need for change, said Urte Jakimaviciute, Senior Director of Market Research at GlobalData. "Lack of supply chain efficiency, transparency and authenticity has been an ongoing issue and the root of many challenges faced by the healthcare companies."
GlobalData cited numerous instances of faulty and counterfeit goods entering markets, which has exacerbated and weakened the global fight against COVID-19: faulty China-produced protective masks and testing kits have been reported by EU countries such as Spain and the Netherlands; Australian Border Force has reportedly seized consignments of personal protective equipment (PPE) that was counterfeit or defective; and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has disabled nine domain names and social media accounts that were selling fake or unauthorized COVID-19 products.
Unless all points in the supply chain are transparent, identifying the source of the transgression or verifying the authenticity of the product is difficult, GlobalData said.
According to Jakimaviciute, healthcare organizations, from manufacturers to distributors, could use blockchain-based systems, which would provide an "open, tamper-proof, distributed record of transactions" and, in turn, "increase accuracy and efficiency".
"Blockchain has broad implications for the healthcare industry. More cases have recently emerged due to the need to simplify and improve security and accuracy for cumbersome, inefficient supply chain processes. While it may be too late to incorporate any sizable blockchain-related solutions to manage the impact of the coronavirus on supply chains, as the technology is still in a proof-of-concept stage, blockchain remains as one of the most promising solutions to facilitate data sharing, improve regulatory compliance and adherence with serialization regulations,” Jakimaviciute concluded.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance